Hideki Iwamoto

Kurume, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 147 publications

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 15, 2026

Strategic driving of the cancer-immunity cycle in HCC: roles of immune, molecular-targeted, and locoregional therapies.

Strategic driving of the cancer-immunity cycle in HCC: roles of immune, molecular-targeted, and locoregional therapies.

Journal: Journal of liver cancer

Published: April 16, 2026

Correspondence to letter to the editor on "Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma".

Correspondence to letter to the editor on "Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma".

Journal: Clinical and molecular hepatology

Published: January 07, 2026

Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.

Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: November 03, 2025

The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt.

The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt.

Journal: Internal medicine (Tokyo, Japan)

Published: October 15, 2025

Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib.

Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib.

Journal: Journal of liver cancer

Published: September 25, 2025

Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma.

Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma.

Journal: Clinical and molecular hepatology

Published: September 08, 2025

Innovation of a Repeatable Microcatheter-accessible Port (ReMAP): Initial Clinical Results Evaluating Feasibility in the Treatment of Hepatocellular Carcinoma.

Innovation of a Repeatable Microcatheter-accessible Port (ReMAP): Initial Clinical Results Evaluating Feasibility in the Treatment of Hepatocellular Carcinoma.

Journal: Interventional radiology (Higashimatsuyama-shi (Japan)

Published: September 02, 2025

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 13, 2025

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 27, 2025

Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study.

Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study.

Journal: PloS one

Published: May 23, 2025

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Journal: Journal of gastroenterology and hepatology

Published: May 18, 2025

Showing 1-12 of 147

Last Updated: 09/26/2026